Thorne Quercetin Phytosome
250 mg quercetin phytosome per capsule
Quercetin phytosome capsules.
Best for: comparing a quercetin phytosome option in Key Facts
View on Amazon · Affiliate link
Safety note: Prescription senolytic drugs can cause serious harm. The research protocols below are not suitable for self-treatment.
Natural senolytic side effects are predominantly mild and transient, occurring in approximately 15–30% of first-cycle users. The most common — mild fatigue, headache, and GI discomfort within 24 hours of dosing — likely represent the normal inflammatory response to dying senescent cells releasing their SASP contents. These typically resolve within 24–48 hours without intervention.
As an Amazon Associate, Stacking Years earns from qualifying purchases.
250 mg quercetin phytosome per capsule
Quercetin phytosome capsules.
Best for: comparing a quercetin phytosome option in Key Facts
View on Amazon · Affiliate link
8 mg fisetin per capsule
Low-dose fisetin with fenugreek galactomannans.
Best for: reviewing a low-dose fisetin label in Key Facts
View on Amazon · Affiliate link
Is it normal to feel worse before feeling better with senolytics?
Yes, for some users. The transient inflammatory signal from dying senescent cells (SASP release) can cause temporary symptom worsening. This typically resolves within 48 hours and subsequent cycles are usually better tolerated as senescent cell burden decreases.
How long should I wait after an injury before taking senolytics?
Wait until wound healing is substantially complete (approximately 2–4 weeks post-injury). The senescent cells involved in wound repair (which produce PDGF-AA and promote healing) should be allowed to complete their function before clearance.
“Senolytic” describes a research goal, not a standardized class of safe supplements. Dasatinib is a prescription tyrosine-kinase inhibitor used in oncology; it can cause cytopenias, fluid retention, bleeding, infection, and drug interactions. Quercetin in a supplement is not equivalent to pharmaceutical dosing or to the intermittent D+Q protocols studied in small trials. Fisetin and other flavonoids have limited long-term safety data at concentrated supplement doses.
In the 2023 randomized phase I IPF pilot, only 12 people were enrolled (six in each arm). Its purpose was feasibility and tolerability, not to establish safety for the general public. A small trial with short follow-up cannot detect uncommon or delayed harms. Trial participants were selected and monitored; results should not be used to justify self-treatment.
Ask whether a clinician has reviewed all prescriptions, supplements, bleeding risks, liver or kidney conditions, and planned procedures. Do not stop a prescribed medicine to make room for an experimental compound. Avoid “pulse” schedules found online unless they are part of a supervised study. Report bruising, unusual bleeding, fever, shortness of breath, severe rash, or persistent symptoms promptly.
People receiving cancer treatment, immunosuppressants, anticoagulants, or medications with narrow therapeutic ranges should not add concentrated supplements without the treating team’s advice. Pregnant or breastfeeding people and children should avoid experimental senolytic regimens outside specialist care.
FAQ
Are occasional doses automatically safer than daily use? Not necessarily; intermittent dosing does not remove drug-specific risks.
Can I monitor senolytic safety with a home blood test? No home panel has been validated to make an unsupervised regimen safe.
Read the D+Q clinical guide and fisetin safety profile.
Research: Randomized phase I D+Q safety and feasibility trial; trial abstract.